Romanowska Malgorzata, Evans Alan, Kellock David, Bray Susan E, McLean Kathleen, Donandt Susanne, Foerster John
Division of Experimental Medicine, University of Dundee, Dundee, Scotland, UK.
PLoS One. 2009;4(4):e5354. doi: 10.1371/journal.pone.0005354. Epub 2009 Apr 28.
BACKGROUND: Wnt5a is a member of the wingless-type patterning regulators important in pre-natal development. The expression and distribution of Wnt5a and its receptors frizzled (fzd) 3 and fzd 5 in adult human skin have not been comprehensively studied to date. METHODOLOGY/PRINCIPAL FINDINGS: We here show that Wnt5a, fzd3, fzd5, as well as fzd6 are restricted to specific layers in normal epidermis, analogous to their zonal distribution in hair follicles, suggesting a role in adult skin differentiation. In line, Wnt5a and fzd5 are both overexpressed and re-distributed in the epidermis of psoriasis which involves disturbed keratinocyte differentiation. Functionally, Wnt5a lowers the concentration of IFN required to induce target genes, and increases the magnitude of IFN target gene induction, suggesting a molecular mechanism underlying IFN hypersensitivity in psoriasis. Finally, we identify nedd8 and the amyloid precursor APP, previously shown to be upregulated in psoriasis, as targets of synergistic IFNalpha/Wnt5a induction. CONCLUSIONS/SIGNIFICANCE: The present data (i) suggest that Wnt5a regulates epidermal differentiation even in adult skin and (ii) identify synergistic induction of type 1 IFN target genes as a novel mode of Wnt5a action. Targeting Wnt5a in the skin may reduce IFN hypersensitivity and be of therapeutical value.
背景:Wnt5a是无翅型模式调控因子家族的成员,在产前发育中起重要作用。迄今为止,Wnt5a及其受体卷曲蛋白(fzd)3和fzd 5在成人皮肤中的表达和分布尚未得到全面研究。 方法/主要发现:我们在此表明,Wnt5a、fzd3、fzd5以及fzd6在正常表皮中局限于特定层,类似于它们在毛囊中的区域分布,提示其在成人皮肤分化中发挥作用。同样,Wnt5a和fzd5在银屑病表皮中均过度表达且重新分布,银屑病涉及角质形成细胞分化紊乱。在功能上,Wnt5a降低诱导靶基因所需的IFN浓度,并增加IFN靶基因诱导的幅度,提示银屑病中IFN超敏反应的潜在分子机制。最后,我们确定NEDD8和淀粉样前体蛋白APP(先前已证实在银屑病中上调)是IFNα/Wnt5a协同诱导的靶标。 结论/意义:本研究数据(i)提示Wnt5a即使在成人皮肤中也调节表皮分化,(ii)确定1型IFN靶基因的协同诱导是Wnt5a作用的一种新模式。针对皮肤中的Wnt5a可能降低IFN超敏反应并具有治疗价值。
J Invest Dermatol. 2010-4-8
Exp Dermatol. 2015-3
J Invest Dermatol. 2007-1
Development. 2022-11-15
Front Pharmacol. 2025-4-29
Front Immunol. 2024-11-29
Clin Cosmet Investig Dermatol. 2021-11-10
J Allergy Clin Immunol. 2020-6
Clin Cancer Res. 2008-10-15
Biochem Biophys Res Commun. 2008-1-11
Br J Dermatol. 2007-12
Cancer Lett. 2007-11-18